A major focus of my research is to characterize the inhibition of drug metabolism. Information gained from in vitro experiments, whether it’s reversible or irreversible inhibition, is used to predict changes in drug clearance for co-administered medications. Clinical studies, which incorporate the use of drugs and their metabolites as putative markers of selective enzymes, are performed to test the predictions and applicability of the in vitro estimates. Drug metabolizing enzymes that are currently studied include: CYP1A, 2C, 2D6, and 3A.